治療用ワクチンの世界市場2019-2023

◆英語タイトル:Global Therapeutic Vaccines Market 2019-2023
◆商品コード:IRTNTR31379
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年5月30日
◆ページ数:123
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:米州、アジア、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Technavio社の本調査レポートでは、治療用ワクチンの世界市場について調べ、治療用ワクチンの市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、治療用ワクチンの市場規模をセグメンテーション別(種類別(癌ワクチン、感染症ワクチン、その他の疾病ワクチン、神経疾患ワクチン、自己免疫疾患ワクチン)、)と地域別(米州、アジア、ヨーロッパ(EMEA))に分けて算出しました。Technavio社は治療用ワクチンの世界市場規模が2019-2023期間中に年平均19%成長すると予測しています。
・サマリー
・レポートの範囲
・治療用ワクチンの市場状況
・治療用ワクチンの市場規模
・治療用ワクチンの市場予測
・治療用ワクチンの世界環境:ファイブフォース分析
・市場セグメンテーション:種類別(癌ワクチン、感染症ワクチン、その他の疾病ワクチン、神経疾患ワクチン、自己免疫疾患ワクチン)
・治療用ワクチンの顧客状況
・主要地域別市場規模:米州、アジア、ヨーロッパ(EMEA)
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

About this market

The market is driven by the growing incidence of malignant and chronic diseases such as HIV, human papillomavirus, cancer, among others. Cancer is one of the malignant diseases that is claiming several lives across countries such as the US, the UK, and Denmark over the past few years. The prevalence of chronic diseases such as Alzheimer’s, asthma, diabetes, and multiple sclerosis are also increasing across the world. Such an increasing outspread of morbid ailments are increasing the demand for therapeutic vaccines. This is expected to drive the growth of the market at a CAGR of more than 19% during the forecast period.

Market Overview

Strong therapeutic pipeline

Key vendors in the therapeutics vaccines market are developing vaccines to resist the outbreak of several infectious and chronic diseases. Several drugs are in the late stage of clinical trials and are expected to receive marketing approval during the forecast period. For instance, Inovio Pharmaceuticals developed VGX-3100 to treat precancers in the cervix. The vaccine is currently in Phase III stage of clinical trials.

Availability of alternative therapies to treat diseases

The cost and time associated with developing a therapeutic vaccine is paving the way for the emergence of alternative treatments such as chemotherapy, and targeted therapies are widely used to treat various cancer types. Also, the availability of several US FDA approved drugs such as PROVENGE for the treatment of prostate cancer in men are hindering the growth of the market.

For the detailed list of factors that will drive and challenge the growth of the therapeutic vaccines market size during 2019-2023, view our report.

Competitive Landscape

The market appears to be concentrated with few players occupying the market share.

Companies such as Aimmune Therapeutics Inc. and Immune Response BioPharma Inc. have intensified the competition. Factors such as the rising incidence and prevalence of diseases and strong therapeutic vaccine pipeline will provide significant growth opportunities for therapeutic vaccine companies. Aimmune Therapeutics Inc., Immune Response BioPharma Inc., Inovio Pharmaceuticals Inc., Novartis AG, and Sanpower Group Co. Ltd. are some of the major companies covered in this report.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY TYPE

Market segmentation by type

Comparison by type

Cancer vaccines – Market size and forecast 2018-2023

Infectious diseases vaccines – Market size and forecast 2018-2023

Other diseases vaccines – Market size and forecast 2018-2023

Neurological diseases vaccines – Market size and forecast 2018-2023

Autoimmune diseases vaccines – Market size and forecast 2018-2023

Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Market trends

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Aimmune Therapeutics, Inc.

Immune Response BioPharma Inc.

Inovio Pharmaceuticals Inc.

Novartis AG

Sanpower Group Co. Ltd.

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Global vaccine market

Exhibit 02: Segments of global vaccine market

Exhibit 03: Market characteristics

Exhibit 04: Market segments

Exhibit 05: Market definition – Inclusions and exclusions checklist

Exhibit 06: Market size 2018

Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 09: Five forces analysis 2018

Exhibit 10: Five forces analysis 2023

Exhibit 11: Bargaining power of buyers

Exhibit 12: Bargaining power of suppliers

Exhibit 13: Threat of new entrants

Exhibit 14: Threat of substitutes

Exhibit 15: Threat of rivalry

Exhibit 16: Market condition – Five forces 2018

Exhibit 17: Type – Market share 2018-2023 (%)

Exhibit 18: Comparison by type

Exhibit 19: Cancer vaccines – Market size and forecast 2018-2023 ($ millions)

Exhibit 20: Cancer vaccines – Year-over-year growth 2019-2023 (%)

Exhibit 21: Infectious diseases vaccines – Market size and forecast 2018-2023 ($ millions)

Exhibit 22: Infectious diseases vaccines – Year-over-year growth 2019-2023 (%)

Exhibit 23: Vaccines under development for infectious diseases

Exhibit 24: Other diseases vaccines – Market size and forecast 2018-2023 ($ millions)

Exhibit 25: Other diseases vaccines – Year-over-year growth 2019-2023 (%)

Exhibit 26: Vaccines under development for other diseases

Exhibit 27: Neurological diseases vaccines – Market size and forecast 2018-2023 ($ millions)

Exhibit 28: Neurological diseases vaccines – Year-over-year growth 2019-2023 (%)

Exhibit 29: Vaccines under development for neurological diseases

Exhibit 30: Autoimmune diseases vaccines – Market size and forecast 2018-2023 ($ millions)

Exhibit 31: Autoimmune diseases vaccines – Year-over-year growth 2019-2023 (%)

Exhibit 32: Vaccines under development for autoimmune diseases

Exhibit 33: Market opportunity by type

Exhibit 34: Customer landscape

Exhibit 35: Market share by geography 2018-2023 (%)

Exhibit 36: Geographic comparison

Exhibit 37: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 38: North America – Year-over-year growth 2019-2023 (%)

Exhibit 39: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 40: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 41: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 42: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 43: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 44: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 45: Key leading countries

Exhibit 46: Market opportunity

Exhibit 47: Vaccines under development

Exhibit 48: Impact of drivers and challenges

Exhibit 49: Vendor landscape

Exhibit 50: Landscape disruption

Exhibit 51: Vendors covered

Exhibit 52: Vendor classification

Exhibit 53: Market positioning of vendors

Exhibit 54: Aimmune Therapeutics Inc. – Vendor overview

Exhibit 55: Aimmune Therapeutics Inc. – Business segments

Exhibit 56: Aimmune Therapeutics Inc. – Organizational developments

Exhibit 57: Aimmune Therapeutics Inc. – Key offerings

Exhibit 58: Immune Response BioPharma Inc. – Vendor overview

Exhibit 59: Immune Response BioPharma Inc. – Key offerings

Exhibit 60: Inovio Pharmaceuticals Inc. – Vendor overview

Exhibit 61: Inovio Pharmaceuticals Inc. – Product segments

Exhibit 62: Inovio Pharmaceuticals Inc. – Organizational developments

Exhibit 63: Inovio Pharmaceuticals Inc. – Key offerings

Exhibit 64: Novartis AG – Vendor overview

Exhibit 65: Novartis AG – Business segments

Exhibit 66: Novartis AG – Organizational developments

Exhibit 67: Novartis AG – Geographic focus

Exhibit 68: Novartis AG – Segment focus

Exhibit 69: Novartis AG – Key offerings

Exhibit 70: Sanpower Group Co. Ltd. – Vendor overview

Exhibit 71: Sanpower Group Co. Ltd. – Key offerings

Exhibit 72: Validation techniques employed for market sizing

Exhibit 73: Definition of market positioning of vendors



【掲載企業】

Aimmune Therapeutics Inc.
Immune Response BioPharma Inc.
Inovio Pharmaceuticals Inc.
Novartis AG
Sanpower Group Co. Ltd.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[治療用ワクチンの世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆